Assessment of diabete treatment of individuals with diabetes type 2, with GLP-1 mimetic, exenatide, response to GLP1 mimetic of GLP-1 treatment, in patients with type 2 diabetes, related to the SNPs rs12255372 (G / T) and rs7903146 (C / T) of TCF7L2 gene

Abstract

Screening for genetic polymorphisms in various populations, said the gene transcription factor TCF7L2 (Transcription Factor 7-Like 2), which has a significant association with T2DM. The TCF7L2 is a potent insulin secretagogue. It was observed that polymorphic variants present in the TCF7L2 gene may result in reduced insulin secretion stimulated by the action of GLP-1 secretion. The incretin effect, had been hampered in carrying the T allele of SNPs rs7903146 and rs 12,255,372 of that gene. These data suggest that in individuals carriers of these variants, the cell b respond less to GLP-1. The treatment of type 2 diabetes with exenatide, an analogue of GLP-1 in subjects with and those without the variants of the polymorphic SNPs rs7903146 (C / T) rs12255372 (G / T) is to evaluate the differences in the response. The indication of incretins to treat type 2 diabetes is aimed at promoting glycemic control through physiological mechanisms, reducing the risk of hypoglycemia and increasing the possibility of better control of postprandial glucose. Moreover, it is a chance to promote increased survival of beta cells. However, some studies have shown that the presence of polymorphic variants of the TCF7L2 gene, determine a reduction in secretion and sensitivity to GLP-1, suggesting that patients with these variants could not be good Responsoris to treatment with GLP-1 or its analogues . The purpose of this study is to evaluate the response to treatment with an agonist of GLP-1 (Exenatide) in subjects with DM2 and carriers of the variant polymorphic SNPs rs7903146 (C / T) and rs12255372 (G / T) of TCF7L2 assessing the relevance this polymorphism in the pattern of drug response. Be genotyped 300 type 2 diabetic patients using Real Time PCR quality, these will be held to select 30 individuals homozygous for the risk allele and 30 without the risk allele for both SNPs. The 2 groups will be treated with exenatide for 2 months and assessed before and after treatment compared to standard biochemical and hormonal. (AU)